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Aims Current evidence on dyslipidaemia management has expanded to novel treatments and very low achieved levels of
low-density lipoprotein cholesterol (LDL-C). We sought to compare the clinical impact of more-intensive vs. less-intensive
LDL-C lowering by means of statins and currently recommended non-statin medications in secondary prevention.
...................................................................................................................................................................................................
Methods
and results
We searched Medline, EMBASE, and Cochrane databases for randomized controlled trials of statins, ezetimibe,
proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, or bile acid sequestrants with >500 patients fol-
lowed for >_1 year. We employed random-effects models using risk ratios (RRs) with 95% confidence intervals
(CIs) to compare outcomes. We included 19 trials (15 of statins, 3 of PCSK9 inhibitors, and 1 of ezetimibe) with
152 507 patients randomly assigned to more-intensive (n = 76 678) or less-intensive treatment (n = 75 829). More-
intensive treatment was associated with 19% relative risk reduction for the primary outcome, major vascular events
(MVEs; RR 0.81, 95% CI 0.77–0.86). Risk reduction was greater across higher baseline levels and greater achieved
reductions of LDL-C. The clinical benefit was significant across varying types of more-intensive treatment and was
consistent for statins (RR 0.81, 95% CI 0.76–0.86) and non-statin agents (PCSK9 inhibitors and ezetimibe; RR 0.85,
95% CI 0.77–0.94) as active (more-intensive) intervention (P-interaction = 0.38). Each 1.0 mmol/L reduction in LDL-
C was associated with 19% relative decrease in MVE. Death, cardiovascular death, myocardial infarction, stroke,
and coronary revascularization also favoured more-intensive treatment.
...................................................................................................................................................................................................
Conclusion Reduction of MVE is proportional to the magnitude of LDL-C lowering across a broad spectrum of on-treatment
levels in secondary prevention. Statin intensification and add-on treatment with PCSK9 inhibitors or ezetimibe are
associated with significant reduction of cardiovascular morbidity in this very high-risk population.
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Introduction
Lowering of low-density lipoprotein cholesterol (LDL-C) halts
the progression of atherosclerosis1,2 and improves clinical out-
comes in patients with atherosclerotic cardiovascular disease
(ASCVD).3 Although statins are established as first-line treatment
for LDL-C lowering, many patients cannot achieve sufficient LDL-
C reduction or tolerate effective doses of statins. Non-statin
agents currently recommended as second-line options in patients
with clinical ASCVD include cholesterol absorption inhibitors
* Corresponding author. Tel: þ41 31 632 45 56, Fax: +41 31 632 89 77, Email: konstantinos.koskinas@insel.ch
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(ezetimibe), bile acid sequestrants, and proprotein convertase
subtilisin-kexin type 9 (PCSK9) inhibitors.4–6
Previous meta-analyses of randomized controlled trials (RCTs)
established the safety and efficacy of statins in primary and secondary
prevention,3 showed a direct relation between the magnitude of
LDL-C lowering and clinical risk reduction,3 and collectively assessed
the cardiovascular effects of variable lipid-lowering interventions
including non-medical treatments (diet and surgical interventions) as
well as medications that are currently not recommended or are con-
traindicated in combination with statins (niacin and fibrates).7
Recently, preliminary evidence of clinical benefit with PCSK9
inhibitors8 was confirmed in large, dedicated outcomes trials.9
Against this background of novel available evidence, we sought to
provide a contemporary quantitative synthesis of the efficacy of
more-intensive vs. less-intensive LDL-C lowering and address the fol-
lowing key questions: (i) assess the relative clinical benefit of statins
and currently recommended non-statin LDL-C-lowering medications
in secondary prevention and (ii) evaluate the magnitude of cardiovas-
cular risk reduction across a wide spectrum of achieved LDL-C
reductions, extending to very low on-treatment levels uniquely
achievable by means of PCSK9 inhibitors. We focused on patients
with established ASCVD, i.e. those at highest cardiovascular risk and
likely to derive maximal benefit from intensive LDL-C lowering.
Methods
Search methods and resources
Methods are described in detail in the Supplementary material online.
The protocol was registered with PROSPERO (CRD42017059343).
Following the Cochrane Handbook recommendations,10 we searched
the following databases [Medline, Embase, and the Cochrane Central
Register of Controlled Trials (CENTRAL)] and websites (www.clinical
trials.gov and www.cardiosource.com) to identify relevant trials of the
competing interventions of interest. We applied a modified broad search
strategy by including relevant keywords (‘statin’, ‘ezetimibe’, ‘PCSK9
inhibitor’, ‘colestipol’, ‘cholestyramine’, ‘low-density lipoprotein choles-
terol’, ‘LDL-C’, and ‘random’) without restrictions on language or year of
publication. We scrutinized the reference lists from all eligible studies to
identify additional citations that would fit our inclusion criteria (see
Supplementary material online, Table S1).
Selection of studies
We considered eligible studies that included >500 patients (to exclude
small studies with unreliable hazard ratios) and reported cardiovascular
outcomes during at least 1 year of follow-up. Inclusion criteria were as
follows: described as randomized, controlled trial; evaluated any compari-
son of the following strategies: statins, ezetimibe, bile acid sequestrants,
PCSK9 inhibitors, or placebo (therapy vs. no therapy or more-intensive
vs. less-intensive intervention or higher vs. lower dose of a medication);
and included secondary-prevention patients (defined by a history of
known ASCVD, i.e. coronary heart disease, peripheral artery disease, or
cerebrovascular disease) or at least 60% secondary-prevention patients.
‘More-intensive’ vs. ‘less-intensive’ interventions included following possi-
ble comparisons: statin vs. control (no statin); more-intensive statin vs.
less-intensive statin; non-statin agent vs. control; and more-intensive non-
statin agent vs. less-intensive non-statin agent. Because the focus of this
study was the effect of LDL lowering on clinical progression of ASCVD,
we excluded studies of patients with significant competing risks (heart
failure or chronic kidney disease), as the clinical benefit of lipid-lowering
therapy is confounded by competing non-atherosclerotic risks.3,11
Data extraction and study outcomes
Two investigators (K.C.K. and G.C.M.S.) scrutinized titles and abstracts of
all items independently and identified eligible trials. Consistent with pre-
vious reports,3,7 we focused on cardiovascular events that are reduced
by LDL-C-lowering therapies. Outcomes from each trial were selected
to most closely approximate the composite endpoint of major vascular
events (MVEs), which consisted of cardiovascular death, myocardial
infarction or other acute coronary syndrome, coronary revascularization,
and stroke when available. Secondary outcomes of interest included
death, cardiovascular death, myocardial infarction, stroke, and coronary
revascularization. Numbers of events in each arm were extracted to cal-
culate risk ratios (RRs). We extracted data based on the intention-to-
treat principle whenever available.
Risk of bias and quality assessment
Trial quality was assessed using Cochrane risk of bias assessment tool.12
Two investigators (G.C.M.S. and R.P.) reviewed the studies and judged
the risk of bias as low, unclear, or high risk.
Statistical analyses
We used DerSimonian and Laird random-effects meta-analysis to calculate
summary RR.13 Heterogeneity was estimated using restricted maximum
likelihood and evaluated using I2; values of 25%, 50%, and 75% represented
mild, moderate, and high heterogeneity, respectively.14 We stratified the
meta-analysis of the primary outcome on a trial level by (i) type of interven-
tion (statin vs. no statin, more-intensive statin vs. less-intensive statin, and
non-statin vs. control), (ii) active intervention (statin or non-statin medi-
cation), (iii) mean baseline LDL-C levels (using the lower tertile across trials
as cut-off), and (iv) mean absolute LDL-C reduction (using the median
value across trials as cut-point). For the primary outcome, random-effects
meta-regression analysis was performed with the reduction of LDL-C lev-
els in each trial as moderator. To calculate absolute effect estimates, we
applied pooled rate ratios and 95% confidence intervals (CIs) to what we
deemed to be the most credible source for baseline risk estimates, i.e. the
control rate of outcomes in the largest trial.15
In view of the time-dependent emergence of clinical benefit with
statins3,16 and to address the possibly confounding effect of shorter
follow-up in trials with PCSK9 inhibitors, we performed the following
sensitivity analyses: (i) we compared PCSK9 inhibitor trials vs. statin trials
with follow-up <_2.2 years (i.e. the median follow-up of the largest PCSK9
inhibitor trial9) and (ii) we compared PCSK9 trials vs. statin trials focusing
only on outcomes up to 2.2 years. For the latter analysis, in statin trials
with follow-up >2.2 years, we derived estimates from reconstructed
time-to-event data of individual trials using Cox regression analysis. The
Kaplan–Meier curves (whenever available) were digitized, and time-to-
event data were reconstructed using a previously described algo-
rithm.17,18 Details are provided in the Supplementary material online.
We explored potential publication bias via its common proxy of small
study effects by visual estimation of funnel plots and Egger’s regression
test.19 All P-values were two tailed with statistical significance set at 0.05,
and CIs were calculated at the 95% level for the overall estimates effect.
Analyses were performed in STATA version 13.0.
Results
This meta-analysis included 19 trials that fulfilled pre-specified criteria
(see Supplementary material online, Figure S1): 15 trials of statins,20–34
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..1 trial of ezetimibe,35 and 3 trials of PCSK9 inhibitors.9,36,37 No eligible
trial of bile acid sequestrants was identified. The characteristics of indi-
vidual trials and patient populations are summarized in Tables 1 and 2
and Supplementary material online, Tables S2–S3. All trials except
one27 were multicentre studies. Overall, 152 507 patients were ran-
domly assigned to more-intensive (n = 76 678) or less-intensive LDL-C
lowering treatment (n = 75 829). Mean follow-up duration was
3.95 years (median 4.3, range 1–6.7 years), yielding 602 587 patient-
years. The definition of more-intensive vs. less-intensive included fol-
lowing three comparisons: (i) statin vs. no statin (placebo, no treat-
ment, or usual care, nine trials20,21,23–27,30,33); (ii) more-statin vs. less-
statin (six trials22,28,29,31,32,34); and (iii) non-statin agent (on top of
statin) vs. placebo (on top of statin) (four trials9,35–37). Table 2 summa-
rizes pooled clinical characteristics for these three groups of trials, indi-
cating higher baseline LDL-C in trials of statin vs. no statin as well as
higher prevalence of diabetes, smoking, and hypertension, a greater
proportion of acute coronary syndrome patients, and shorter follow-
up in trials with non-statin agents.
Primary outcome
Figure 1 presents a random-effects meta-analysis of the primary out-
come. There were 25 260 MVEs, 11 591 for more-intensive vs. 13 669
for less-intensive treatment. The summary estimate showed a 19%
....................................................................................................................................................................................................................
Table 1 Study characteristics of included trials
Trial name Publication
year
Recruitment
period (years)
No. of
centres
Active intervention
(more intensive)
Control (less
intensive)
Follow-up
(years)a
Patients
randomized
4S 1994 1988–1989 94 Simvastatin 20–40 mg Placebo 5.4 4444
CARE 1996 1989–1991 80 Pravastatin 40 mg Placebo 5 4159
Post-CABG 1997 1989–1991 7 Lovastatin 40–80 mg Lovastatin 2.5–5 mg 4.3 1351
LIPID 1998 1990–1992 87 Pravastatin 40 mg Placebo 6.1 9014
GISSI-P 2000 1993–1996 172 Pravastatin 20 mg No treatment 2 4271
LIPS 2002 1996–1998 57 Fluvastatin 80 mg Placebo 3.9 1677
HPS 2002 1994–1997 69 Simvastatin 40 mg Placebo 5 20 536
GREACE 2002 1998–2000 1 Atorvastatin 10–80 mg Usual careb 3 1600
PROVE-IT 2004 2000–2001 349 Atorvastatin 80 mg Pravastatin 40 mg 2 4162
A to Z 2004 1999–2003 322 Simvastatin 40–80 mg Placebo titrated to
Simvastatin 20mg
2 4497
ALLIANCE 2004 1995–2002 16 Atorvastatin 10–80 mg Usual careb 4.5 2442
TNT 2005 1998–1999 256 Atorvastatin 80 mg Atorvastatin 10 mg 4.9 10 001
IDEAL 2005 1999–2001 190 Atorvastatin 40–80 mg Simvastatin 20–40mg 4.8 8888
SPARCL 2006 1998–2001 205 Atorvastatin 80 mg Placebo 4.9 4731
SEARCH 2010 1998–2001 88 Simvastatin 80 mg Simvastatin 20 mg 6.7 12 064
IMPROVE-IT 2015 2005–2010 1147 Ezetimibe 10 mg plus
simvastatin 40 mg
Placebo plus simvasta-
tin 40 mg
6 18 144
ODYSSEY
LONG TERM
2015 2012–2015 320 Alirocumab 150 mg
Q2W plus high-dose
statin or statin ther-
apy at the maximum
tolerated dose
Placebo Q2W plus
high-dose statin or
statin therapy at the
maximum tolerated
dose
1.34 2341
SPIRE-2 2017 2013–2016 1568 Bococizumab 150 mg
Q2W plus statin
(atorvastatin >_40 mg
daily; rosuvastatin
>_20 mg or simvasta-
tin >_40 mg unless not
tolerated)
Placebo Q2W plus
statin (atorvastatin
>_40 mg daily; rosu-
vastatin >_20 mg or
simvastatin >_40 mg
unless not
tolerated)
1 10 621
FOURIER 2017 2013–2015 1242 Evolocumab 140 mg
Q2W or 420 mg QM
plus statin (at least
atorvastatin 20mg)
Placebo Q2W or QM
plus statin (at least
atorvastatin 20mg)
2.2 27 564
aMean or median (as reported in respective trial).
bUsual care was defined in GREACE as lifestyle interventions (diet and exercise) or lipid-lowering medications left at the discretion of treating physicians. In ALLIANCE, patients
allocated to usual care were maintained on the lipid-lowering programme already prescribed prior to enrolment, and adjustments in lipid therapy were made entirely at the dis-
cretion of regular physicians.
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..relative risk reduction (RRR) for MVE in favour of more-intensive treat-
ment (RR 0.81, 95% CI 0.77–0.86; P < 0.001, I2 79%; Figure 1). With
respect to the type of intervention, the benefit was greater in trials com-
paring statin vs. no statin (RR 0.77, 95% CI 0.71–0.83) than in trials of
more-statin vs. less-statin (RR 0.88, 95% CI 0.82–0.93) or trials of non-
statin vs. placebo (RR 0.85, 95% CI 0.77–0.95) (P-interaction = 0.03).
Stratified meta-analyses are summarized in Figure 2 and detailed in
Supplementary material online, Figures S2–S6. The observed benefit
was consistent in trials with statin20–34 and those with a non-statin
agent (i.e. ezetimibe or PCSK9 inhibitor)9,35–37 as active treatment
(P-interaction = 0.38, see Supplementary material online, Figure S2).
The magnitude of benefit was greater in trials with mean baseline
....................................................................................................................................................................................................................
Table 2 Pooled clinical characteristics across trials
Statin vs. no statin
(n 5 52 874)
More statin vs.
less statin (n 5 40 963)
Non-statin agent vs.
placebo (n 5 58 670)
Age (years)a 60.6 61.9 62.7
Diabetes mellitus 9980/52 874 (18.9%) 5630/39 612 (14.2%) 20 809/58 670 (35.5%)
Female gender 11 551/52 874 (21.8%) 7772/40 963 (19%) 15 834/58 670 (27%)
Smoking 8128/51 274 (15.8%) 8181/40 963 (20%) 17 122/58/665 (29.2%)
Hypertension 20 958/50 432 (41.6%) 17 744/39 612 (44.8%) 41 776/56 320 (74.1%)
Acute coronary syndromeb 0 (0%) 8659/40 963 (21.1%) h18 144/58, 670 (30.9%)
Baseline LDL-C (mmol/L) 3.72 2.76 2.63
Reduction in LDL-C (mmol/L)c 1.04 0.54 1.15
Follow-up (years)a 4.83 4.77 3.12
aWeighed means derived from mean or median values, as reported in respective individual trials.
bIn the ‘more statin vs. less statin’ group, two trials enrolled patients with acute coronary syndrome (ACS): PROVE-IT included patients with ACS in the preceding 10 days prior
to enrolment and A to Z included ACS patients stabilized for at least 12 h within 5 days after symptom onset. In the ‘non-statin vs. placebo’ group, one trial (IMPROVE-IT)
included patients with ACS in the preceding 10 days prior to enrolment.
cDifference in achieved LDL-C between treatment arms.
Overall  (I2 = 79%, p < 0.001)
SPIRE-2
SEARCH
TNT
HPS
FOURIER
Subtotal  (I2 = 75%, p = 0.007)
A to Z
SPARCL
Non-statin vs. placebo
IDEAL
CARE
PROVE-IT
Trial
IMPROVE-IT
Subtotal (I2 = 45%, p = 0.108)
GREACE
Statin vs. no statin
ODYSSEY LONG TERM
LIPS
ALLIANCE
4S
LIPID
Post-CABG
GISSI-P
Subtotal  (I2 = 69%, p = 0.001)
More statin vs. less statin
2017
2010
2005
2002
2017
2004
2006
2006
1996
2004
Year
2015
2002
2015
2002
2004
1994
1998
1997
2000
179/5312
1477/6031
434/4995
2033/10269
1271/13784
309/2265
334/2365
533/4439
212/2081
470/2099
Intervention
2572/9077
96/800
27/1553
181/844
289/1217
431/2221
557/4512
85/676
101/2138
224/5309
1553/6033
548/5006
2585/10267
1512/13780
343/2232
407/2366
608/4449
274/2078
543/2063
Control
2742/9067
196/800
26/788
222/833
333/1225
622/2223
715/4502
103/675
113/2133
0.81 (0.77 to 0.86)
0.80 (0.66 to 0.97)
0.95 (0.89 to 1.01)
0.79 (0.70 to 0.89)
0.79 (0.75 to 0.83)
0.84 (0.78 to 0.90)
0.85 (0.77 to 0.95)
0.89 (0.77 to 1.02)
0.82 (0.72 to 0.94)
0.88 (0.79 to 0.98)
0.77 (0.65 to 0.91)
0.85 (0.76 to 0.95)
 RR (95% CI)
0.94 (0.90 to 0.98)
0.88 (0.82 to 0.93)
0.49 (0.39 to 0.61)
0.53 (0.31 to 0.90)
0.80 (0.68 to 0.96)
0.87 (0.76 to 1.00)
0.69 (0.62 to 0.77)
0.78 (0.70 to 0.86)
0.82 (0.63 to 1.08)
0.89 (0.69 to 1.16)
0.77 (0.71 to 0.83)
100.00
4.10
7.32
5.86
7.53
7.12
19.81
5.28
5.51
6.16
4.63
6.19
Weight
7.64
33.63
3.50
0.97
4.57
5.43
6.18
6.31
2.83
2.90
46.56
Favours more intensive treatment Favours less intensive treatment
1.2 .5 2 5
 Major vascular events
Figure 1 Random-effects meta-analysis of more-intensive vs. less-intensive LDL-C-lowering treatment for the primary outcome of major vascular
events. Trials are stratified by the type of intervention. Risk ratio (RR) estimates according to intention-to-treat principle for all trials. Boxes and horizon-
tal lines represent the respective RR and 95% confidence interval (CI) for each trial. The vertical solid line on the forest plot represents the point estimate
of RR = 1. The red dashed line represents the point estimate of overall RR. Box sizes are proportional to weight of respective trial result. Diamonds rep-
resent the 95% CI for pooled estimates of the effect and are centred on pooled RR. Heterogeneity estimate of I2 accompanies the summary estimate.
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LDL-C >_3.0 mmol/L vs. <3.0 mmol/L (P-interaction = 0.004) and with
LDL-C reduction >_1.0 mmol/L vs. <1.0 mmol/L (P-interaction =
0.002). Figure 3 provides a descriptive summary indicating greater
RRR across higher baseline levels as well as greater achieved reduc-
tion of LDL-C (see Supplementary material online, Table S4).
Meta-regression analysis showed a significant, inverse association
between the RR of the primary endpoint and LDL-C reduction (slope
0.19, 95% CI 0.28 to 0.10; P < 0.001; Figure 4). Each 1.0 mmol/L
reduction in LDL-C was associated with a 19% RRR of MVE.
Using the observed rate of MVE in the control group of the largest
of included studies as a baseline9 (1512 events in 13 780 patients over
2.2 years corresponding to 53 events per 1000 patients per year),
more-intensive LDL-lowering treatment was associated with 10
fewer MVE per 1000 patients per year (95% CI, 7–12 less events)
(see Supplementary material online, Table S5).
Sensitivity analyses for the primary
outcome
In a sensitivity analysis of the primary outcome, we did not detect any
variation in the clinical benefit of more-intensive treatment in trials of
statins with follow-up <_2.2 year24,28,29 vs. trials of PCSK9 inhibitors
(RR 0.87, 95% CI 0.80–0.94 vs. RR 0.81, 95% CI 0.80–0.89, respec-
tively; P-interaction = 0.36) (see Supplementary material online,
Figure S7). Similarly, in an analysis using data of statin trials with either
follow-up duration <_2.2 years24,28,29 or with outcomes estimated up
to 2.2 years as derived from the available Kaplan–Meier
curves,20,21,23,25,26,30–33 we found consistent risk reduction of MVE
with statins and PCSK9 inhibitors (P-interaction = 0.72) (see
Supplementary material online, Figure S8).
Secondary outcomes
Random-effects meta-analyses for secondary outcomes showed signifi-
cant risk reduction for death (10%), cardiovascular death (14%), myo-
cardial infarction (24%), stroke (19%), and coronary revascularization
(19%) in favour of more-intensive treatment (P < 0.001 for all end-
points; see Supplementary material online, Figures S9–S14). The effect
on mortality was significant in trials comparing statin vs. no statin (RR
0.85, 95% CI 0.78–0.92 for death and RR 0.78, 95% CI 0.73–0.84 for car-
diovascular death), whereas no survival benefit of more-intensive treat-
ment was observed with other two types of intervention (Figure 5).
Risk of bias assessment
Overall risk of bias was rated as low in all studies (see Supplementary
material online, Table S6); four trials24,27,30,32 were graded high risk
Figure 2 Stratified analyses for major vascular events. RR and
corresponding CI for subgroups from individual trials were pooled
and interactions were evaluated by random-effects meta-analyses.
Boxes and horizontal lines represent the respective RR and 95% CI
for each stratum. In the stratification by intervention, the ‘more-
intensive’ vs. ‘less-intensive’ stratum includes trials comparing more-
statin vs. less-statin (n = 6) and trials comparing non-statin vs.
placebo (n = 4).
Figure 3 Relative risk reduction of the primary endpoint plotted against categories of baseline LDL-C (x-axis) and reduction in LDL-C (i.e. differ-
ence in achieved LDL-C between treatment arms; z-axis). Individual trials corresponding to each of the six groups are indicated below the graph.
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Downloaded from https://academic.oup.com/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehx566/4562493
by E-Library Insel user
on 06 February 2018
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
.
regarding blinding (open-label studies). There was no indication for
small-study effect as suggested by visual assessment of funnel plots
(see Supplementary material online, Figure S15) and Egger’s test
(P = 0.10). Sensitivity analyses with respect to trial quality showed no
substantive differences (Supplementary material online).
Discussion
The salient findings of this meta-analysis of 19 RCTs including >152 000
patients and >25 000 primary outcome events can be summarized as
follows. First, more-intensive vs. less-intensive LDL-C lowering by
means of currently recommended medications resulted in 19% reduc-
tion of MVE in the context of secondary prevention. Second, each
1.0 mmol/L reduction in LDL-C was associated with 19% RRR for MVE
across a broad spectrum of baseline and on-treatment LDL-C levels.
Third, the clinical benefit was significant across varying modes of
‘more-intensive’ treatment but was more robust for the comparison
of statin vs. no statin (when compared with the benefit yielded by statin
intensification or addition of a non-statin agent). Statins and non-statin
agents (PCSK9 inhibitors and ezetimibe) were associated with consis-
tent clinical benefit (RR 0.81 vs. 0.85, respectively; P-interaction = 0.38).
Fourth, the magnitude of derived benefit was greatest across higher
baseline LDL-C levels and greater achieved LDL-C reductions. Fifth,
more-intensive treatment resulted in decrease of all-cause and cardio-
vascular death, but the survival benefit was confined to studies compar-
ing statin vs. no statin. These findings may have implications with
respect to recommended first- and second-line LDL-lowering treat-
ments in patients at very-high cardiovascular risk.
The beneficial cardiovascular impact of statin treatment is well
established.3,4 This meta-analysis provides an updated quantitative
assessment of current evidence in the setting of secondary preven-
tion by incorporating, for the first time to our knowledge, trials of
non-statin agents—studies that included patients with lower baseline
LDL-C levels, markedly decreased on-treatment levels, and more
intense background cholesterol-lowering therapies (moderate-35 or
high-intensity statin9,37) compared with earlier RCTs of statins. Our
findings extend previous evidence by demonstrating significant reduc-
tions in the risk of MVE across the spectrum of treatment modes,
including medications that were recently introduced in clinical prac-
tice9,36 or recently appreciated to improve prognosis.35 Of note, the
four non-statin trials included in this report contributed 60 000 of
all 152 500 patients—i.e. more than the sum of patients in ‘more- vs.
less-statin’ trials included in the Cholesterol Treatment Trialists
Collaboration (CTTC) meta-analysis.3
Stratified analyses provided additional important insights. The cardi-
ovascular benefit of more-intensive LDL-C lowering was significant
across baseline LDL-C levels but was comparatively more pro-
nounced in the context of higher baseline levels. The CTTC patient-
level meta-analysis previously showed no heterogeneity in risk reduc-
tion across baseline LDL-C levels ranging between <2.0 mmol/L
and >4.0 mmol/L.3 The discordant findings in our analysis should be
viewed in light of the inclusion of a large number of patients with very
low achieved LDL-C as well as our focus on secondary-prevention
RCTs vs. inclusion also of primary-prevention trials in the CTTC
meta-analysis.3 As a result of our study design, this analysis included 13
of 26 trials (87 500 of 170 000 patients) analysed in the CTTC meta-
analysis3 and 6 additional RCTs not included in the CTTC report.
A major focus of this analysis was the assessment of cardiovascular
outcomes associated with statins and non-statin medications. Risk
reduction for MVE was significant with all types of intervention
assessed, but was relatively more pronounced for statin vs. no statin
when compared with either statin intensification or addition of a
non-statin agent. The CTTC meta-analysis also showed greater
reduction of the (unadjusted) risk of MVE in statin vs. control trials
compared with more-statin vs. less-statin trials (RR 0.73 vs. 0.87).3
Interpretation of our findings requires consideration of differences in
study design and patient populations across trials that cannot be fully
addressed in any trial-level meta-analysis. The findings of higher base-
line LDL-C in trials comparing statin vs. no statin, as well more
adverse cardiovascular risk profile (e.g. two-fold higher proportion of
diabetic patients) and considerably shorter follow-up duration in tri-
als of non-statin agents, are notable in this respect. Importantly, we
GREACE
4S
FOURIER
SPARCL
Post-CABG
PROVE-IT
TNT
IDEAL
IMPROVE-IT
SEARCH
A to Z
ALLIANCE
GISSI-P
LIPS
HPS
LIPID
CARE
0 0.25 0.750.50 1.501.25 1.751.0 2.0
Reduction in LDL-C (mmol/l) 
SPIRE-2
ODYSSEY
LONG TERM
-0.8
-0.6
-0.4
-0.2
0
Ezetimibe
PCSK9-Inhibitors
Statins
Lo
gR
R
Figure 4 Meta-regression of major vascular events with reduc-
tion in LDL-C (mmol/L) in each trial as moderator. Circle size
represents the weight each trial was given in the analysis. The meta-
regression slope, derived from trial-level analysis of included trials, is
indicated by the solid line and the 95% CI by the dashed lines.
Statin vs. no statin
Death
Cardiovascular death
More statin vs. less statin
Death
Cardiovascular death
Non-statin vs. placebo
Death
Cardiovascular death
Outcome
2656/26447
1434/23566
1796/20505
893/13411
1721/29726
816/28173
Intrvention
3107/26427
1825/23549
1857/20458
919/13389
1726/28944
812/28156
Control
0.85 (0.78 to 0.92)
0.78 (0.73 to 0.84)
0.95 (0.87 to 1.03)
0.96 (0.86 to 1.08)
0.99 (0.89 to 1.10)
1.00 (0.91 to 1.10)
RR (95% CI)
48%
3%
25%
23%
31%
0%
I2
Favours more intensive treatment Favours less intensive treatment 
1.5 2
Figure 5 Summary estimates for secondary outcomes of all-
cause and cardiovascular death. Trials are stratified by the type of
intervention. RR and corresponding CI for subgroups from individ-
ual trials were pooled by random-effects meta-analyses. Boxes and
horizontal lines represent the respective RR and 95% CI.
6 K.C. Koskinas et al.
Downloaded from https://academic.oup.com/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehx566/4562493
by E-Library Insel user
on 06 February 2018
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
.
found no variation in clinical benefit afforded by statins (in aggregate)
vs. non-statin agents as active, ‘more-intensive’ treatment. Thereby,
against a background of established evidence of cardiovascular bene-
fit conferred by statins, the findings of this study provide quantitative
evidence of incremental clinical benefit with non-statin agents
(PCSK9 inhibitors and ezetimibe). Collectively, our findings substanti-
ate current statements recommending statins (up-titrated to the
highest tolerable doses) as first-line treatment for LDL-C lowering in
patients at very high risk,5,6 and they support the use of PCSK9
inhibitors and ezetimibe as valuable add-on therapies in statin-treated
patients requiring additional LDL-C lowering.
Meta-regression analysis showed 19% RRR of MVE per 1.0 mmol/L
lowering of LDL-C across a broad range of achieved levels (see
Supplementary material online, Figure S16), extending to levels lower
than the currently recommended targets.4–6 The magnitude of risk
reduction with ezetimibe was consistent with the expected reduction
based on the observed LDL-C lowering (i.e. within the CI of the
regression line), whereas it was lower than expected for the given
LDL-C decrease for the two largest PCSK9 inhibitor trials.9,37 This
finding requires cautious interpretation. First, the use of primarily
high-intensity statin as background therapy in FOURIER9 and SPIRE-
237 (i.e. control treatment similar to the active treatment in earlier
statin trials) may have resulted in relatively smaller potential for incre-
mental clinical benefit in response to marked additional LDL-C
reduction. Second, it has been postulated that a larger treatment
effect might be expected if the follow-up duration of PCSK9 inhibitor
trials had been longer.9 This notion is substantiated in part by our
sensitivity analyses showing consistent benefit with PCSK9 inhibitors
and statins when adjusting for differing follow-up duration; however,
in the absence of longer term outcomes data with PCSK9 inhibitors,
these findings remain hypothesis generating. This analysis overall sup-
ports the concept that lower LDL-C is better with respect to clinical
prognosis but cannot exclude the possibility that the proportional
clinical benefit for a given degree of LDL-C reduction may be attenu-
ated at relatively low baseline and extremely low achieved levels.
Along these lines, Ference et al.38 recently showed a log-linear associ-
ation between LDL-C lowering and cardiovascular risk.
In patients with ASCVD and inadequately controlled hypercholes-
terolaemia despite evidence-based statin therapy, add-on treatment
with non-statin agents is currently recommended in appropriate
patients based on the anticipated incremental LDL-C reduction as well
associated reduction in cardiovascular risk.4,5 Ezetimibe is associated
with comparable risk reduction for MVE per unit of LDL lowering
(Figure 4) but more potently reduces LDL-C levels (20–24%5,35) than
up-titration of a potent satin from moderate dose to high dose (around
6–10% on average5). Along these lines, PCSK9 inhibitors (rather than
ezetimibe) might be a reasonable second-line option in patients with
markedly elevated LDL-C levels, despite high-intensity (or maximally
tolerated) statin treatment. In this context, the associated risk reduc-
tion with PCSK9 inhibitors would be greater in absolute terms (albeit
proportionally smaller per unit of LDL-C lowering) than that conferred
by ezetimibe, given the considerably larger LDL-C reduction achieved
by means of PCSK9 inhibition (50–60%).
In this data set, 100 patients would need to be treated with more-
intensive LDL-C lowering over a period of 1 year to prevent one
MVE. It should be noted that this calculation depends largely on the
absolute risk of the reference population. Although our approach of
using event rates of the largest—and one of the most contempo-
rary—of included studies9 for baseline risk estimates is consistent
with previous reports,15 inherent limitations of such assumptions
(including marked heterogeneity in absolute risk across trials) need
to be considered.
The survival benefit associated with more-intensive LDL-C lowering
was overall significant but confined to trials comparing statin vs. no sta-
tin. This observation is along the lines of the CTTC meta-analysis3
showing an effect of additional LDL-C lowering on coronary heart dis-
ease mortality only in trials of statin vs. control. This finding might relate
to evidence-based therapies that reduce cardiovascular mortality in
more recent (‘more-statin vs. less-statin’, PCKS9 inhibitior, or ezeti-
mibe) trials compared with earlier trials that compared statin vs. no sta-
tin (see Supplementary material online, Figure S17).
This study has several limitations. As in all trial-level meta-analyses,
lack of individual patient data precluded analyses in pre-specified
patient subgroups or full evaluation to identify patient characteristics
associated with maximal clinical benefit. Meta-regression techniques
on a trial level require cautious interpretation and are presented as
hypothesis generating. There is a risk of confounding factors, ecological
bias, and the multiple subgroup analyses increase the probability of
type I error.39 Although random-effects pooling reduces heterogene-
ity, the heterogeneity observed among studies with different baseline
cardiovascular risk and background therapy is substantial and acknowl-
edged as a notable limitation. The composite primary endpoint was
not identical across trials; however, our definition of MVE closely
resembles the respective endpoint selection in previous meta-analy-
ses.7 Only four trials of non-statin agents were included; these studies,
however, contributed 40% of patients one-third of primary-outcome
events to the meta-analysis. One of the included PCSK9 inhibitor trials
was terminated early due to antidrug antibodies and attenuation of
LDL lowering over time37; development of bococizumab has there-
fore been discontinued. Although our sensitivity analyses sought to
address the shorter follow-up of current trials with PCSK9 inhibitors,
studies with longer follow-up are warranted to definitively evaluate
long-term clinical efficacy of these medications. In view of the high
cost of monoclonal antibody treatments, cost-effectiveness aspects
for PCSK9 inhibitors not addressed in the present analysis will be
essential for future recommendations regarding their clinical use.40,41
Assessment of safety of LDL-C-lowering interventions was not the
focus of this analysis but has been addressed in previous meta-
analyses of statins3 and RCTs of non-statin agents. Finally, patient
enrolment and follow-up in the included trials extended from 1988
to 2017, a time frame during which medical treatment, non-medical
therapies (e.g. revascularization), and cardiovascular event rates have
changed in patients with established ASCVD.
Supplementary material
Supplementary material is available at European Heart Journal online.
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Schulz KF, Weeks L, Sterne JA; Cochrane Bias Methods Group; Cochrane
Statistical Methods Group. The Cochrane Collaboration’s tool for assessing risk
of bias in randomised trials. BMJ 2011;343:d5928.
13. DerSimonian R, Laird N. Meta-analysis in clinical trials revisited. Contemp Clin
Trials 2015;45(Pt A):139–145.
14. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med
2002;21:1539–1558.
15. Smeeth L, Haines A, Ebrahim S. Numbers needed to treat derived from meta-
analyses—sometimes informative, usually misleading. BMJ 1999;318:1548–1551.
16. Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, Voysey M,
Gray A, Collins R, Baigent C. The effects of lowering LDL cholesterol with statin
therapy in people at low risk of vascular disease: meta-analysis of individual data
from 27 randomised trials. Lancet 2012;380:581–590.
17. Guyot P, Ades AE, Ouwens MJ, Welton NJ. Enhanced secondary analysis of sur-
vival data: reconstructing the data from published Kaplan-Meier survival curves.
BMC Med Res Methodol 2012;12:9.
18. Piccolo R, Feres F, Abizaid A, Gilard M, Morice MC, Hong MK, Kim HS,
Colombo A, Bhatt DL, Palmerini T, Stone GW, Windecker S, Valgimigli M. Risk
of early adverse events after clopidogrel discontinuation in patients undergoing
short-term dual antiplatelet therapy. an individual participant data analysis. JACC
Cardiovasc Interv 2017;10:1621–30.
19. Mavridis D1, Salanti G. Exploring and accounting for publication bias in mental
health: a brief overview of methods. Evid Based Ment Health 2014;17:11–15.
20. 4S randomised trial of cholesterol lowering in 4444 patients with coronary heart
disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:
1383–1389.
21. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L,
Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E. The effect of pravas-
tatin on coronary events after myocardial infarction in patients with average cho-
lesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J
Med 1996;335:1001–1009.
22. The Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggres-
sive lowering of low-density lipoprotein cholesterol levels and low-dose anticoa-
gulation on obstructive changes in saphenous-vein coronary-artery bypass grafts.
N Engl J Med 1997;336:153–162.
23. The Long-Term Intervention with Pravastatin in Ischaemic Disease Study Group.
Prevention of cardiovascular events and death with pravastatin in patients with
coronary heart disease and a broad range of initial cholesterol levels. N Engl J
Med 1998;339:1349–1357.
24. GISSI Prevenzione Investigators. Results of the low-dose (20 mg) pravastatin
GISSI Prevenzione trial in 4271 patients with recent myocardial infarction: do
stopped trials contribute to overall knowledge? GISSI Prevenzione Investigators
(Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico). Ital
Heart J 2000;1:810–820.
25. Serruys PW, de Feyter P, Macaya C, Kokott N, Puel J, Vrolix M, Branzi A,
Bertolami MC, Jackson G, Strauss B, Meier B. Fluvastatin for prevention of car-
diac events following successful first percutaneous coronary intervention: a
randomized controlled trial. JAMA 2002;287:3215–3222.
26. Heart Protection Study Collaborative Group. MRC/BHF heart protection study
of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a rando-
mised placebo-controlled trial. Lancet 2002;360:7–22.
27. Athyros VG, Papageorgiou AA, Mercouris BR, Athyrou VV, Symeonidis AN,
Basayannis EO, Demitriadis DS, Kontopoulos AG. Treatment with atorvastatin
to the National Cholesterol Educational Program goal versus ‘usual’ care in sec-
ondary coronary heart disease prevention. The GREek Atorvastatin and
Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin 2002;18:
220–228.
28. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal
SV, Hill KA, Pfeffer MA, Skene AM. Intensive versus moderate lipid lowering
with statins after acute coronary syndromes. N Engl J Med 2004;350:
1495–1504.
29. de Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KA, White HD, Rouleau JL,
Pedersen TR, Gardner LH, Mukherjee R, Ramsey KE, Palmisano J, Bilheimer DW,
Pfeffer MA, Califf RM, Braunwald E. Early intensive vs a delayed conservative sim-
vastatin strategy in patients with acute coronary syndromes: phase Z of the A to
Z Trial. JAMA 2004;292:1307–1316.
30. Koren MJ, Hunninghake DB; ALLIANCE Investigators. Clinical outcomes in
managed-care patients with coronary heart disease treated aggressively in lipid-
lowering disease management clinics: the ALLIANCE study. J Am Coll Cardiol
2004;44:1772–1779.
31. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM,
Greten H, Kastelein JJ, Shepherd J, Wenger NK; Treating to New Targets (TNT)
Investigators. Intensive lipid lowering with atorvastatin in patients with stable
coronary disease. N Engl J Med 2005;352:1425–1435.
32. Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I,
Larsen ML, Bendiksen FS, Lindahl C, Szarek M, Tsai J; Incremental Decrease in
End Points Through Aggressive Lipid Lowering (IDEAL) Study Group. High-
dose atorvastatin vs usual-dose simvastatin for secondary prevention after
myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA
2005;294:2437–2445.
33. Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, Hennerici M,
Rudolph AE, Sillesen H, Simunovic L, Szarek M, Welch KM, Zivin JA; Stroke
Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL)
Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N
Engl J Med 2006;355:549–559.
34. Armitage J, Bowman L, Wallendszus K, Bulbulia R, Rahimi K, Haynes R, Parish S,
Peto R, Collins R. Intensive lowering of LDL cholesterol with 80 mg versus
20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-
blind randomised trial. Lancet 2010;376:1658–1669.
8 K.C. Koskinas et al.
Downloaded from https://academic.oup.com/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehx566/4562493
by E-Library Insel user
on 06 February 2018
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
.
35. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius
H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P, Im
K, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E,
Califf RM. Ezetimibe added to statin therapy after acute coronary syndromes. N
Engl J Med 2015;372:2387–2397.
36. Robinson JG1, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, Stroes ES,
Langslet G, Raal FJ, El Shahawy M, Koren MJ, Lepor NE, Lorenzato C, Pordy R,
Chaudhari U, Kastelein JJ; ODYSSEY LONG TERM Investigators. Efficacy and
safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med.
2015;372:1489–99.
37. Ridker PM, Revkin J, Amarenco P, Brunell R, Curto M, Civeira F, Flather M, Glynn
RJ, Gregoire J, Jukema JW, Karpov Y, Kastelein JJ, Koenig W, Lorenzatti A, Manga P,
Masiukiewicz U, Miller M, Mosterd A, Murin J, Nicolau JC, Nissen S, Ponikowski P,
Santos RD, Schwartz PF, Soran H, White H, Wright RS, Vrablik M, Yunis C, Shear
CL, Tardif JC; SPIRE Cardiovascular Outcome Investigators. Cardiovascular efficacy
and safety of bococizumab in high-risk patients. N Engl J Med 2017;376:1527–1539.
38. Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, Hegele
RA, Krauss RM, Raal FJ, Schunkert H, Watts GF, Borén J, Fazio S, Horton JD,
Masana L, Nicholls SJ, Nordestgaard BG, van de Sluis B, Taskinen MR,
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